Literature DB >> 8578445

Thrombin specificity.

M C Guillin1, A Bezeaud, M C Bouton, M Jandrot-Perrus.   

Abstract

A model of thrombin interaction with distinct substrates or ligands has been derived from the crystallographic studies of thrombin-inhibitors complexes, and buttressed by functional studies with mutant thrombins, thrombin proteolytic derivatives or antibodies against thrombin. The unique specificity of thrombin for its substrates and ligands may be ascribed to multiple interactions with both the active site cleft and exosite(s) distinct from the active site. Two prominent insertion loops around Trp 50 and Trp 148 project over the active site cleft and play an important role in the substrates selection. Several substrates (fibrinogen, thrombin receptor, heparin cofactor II) or ligands (thrombomodulin, glycoprotein Ib) interact with a large exosite located on the surface of the loop segment 65-76, mainly constituted of basic amino acids, designated anion binding exosite 1. Interaction with these various macromolecules appears to involve a limited number of residues within the large exosite 1. It is conceivable that exosite 1 contains distinct subsites, although most of them may overlap. A second basic exosite (anion binding exosite 2) is located close to the carboxy-terminal B chain helix. Exosite 2 interacts with heparin, the chondroitin sulfate moiety of thrombomodulin and prothrombin activation fragment 2. Interaction of ligands with either exosite 1 or exosite 2 leads to conformational changes of the thrombin molecule, that may be important determinants of thrombin specificity. Whether exosite 2 cooperates with exosite 1 for thrombin interaction with fibrin(ogen) or the thrombin receptor remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578445

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Hyperproduction of fibrin and inefficacy of antithrombin III and alpha2 macroglobulin in the presence of bacterial porins.

Authors:  Biagio Di Micco; Pierpaolo Di Micco; Marilena Lepretti; Paola Stiuso; Giovanna Donnarumma; Maria R Iovene; Rita Capasso; Maria A Tufano
Journal:  Int J Exp Pathol       Date:  2005-08       Impact factor: 1.925

2.  Characterization of bothrojaracin interaction with human prothrombin.

Authors:  R Q Monteiro; P E Bock; M L Bianconi; R B Zingali
Journal:  Protein Sci       Date:  2001-09       Impact factor: 6.725

Review 3.  Thrombin inhibitors from different animals.

Authors:  A M Tanaka-Azevedo; K Morais-Zani; R J S Torquato; A S Tanaka
Journal:  J Biomed Biotechnol       Date:  2010-10-04

Review 4.  Molecular and functional diversity of vascular endothelial growth factors.

Authors:  Yasuo Yamazaki; Takashi Morita
Journal:  Mol Divers       Date:  2006-11       Impact factor: 3.364

5.  Engineering a protease-based and site-specific PEGylation-based strategy for the controlled release of exenatide.

Authors:  Aihong Zhang; Yin Lin; Shirly Nong; Wei Zhao; Mei Dong
Journal:  RSC Adv       Date:  2020-06-30       Impact factor: 4.036

6.  Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.

Authors:  Xianli Niu; Shirong Nong; Xiaomin Zhang; Xiangyang Li; Cheng Wang; Wei Li; Tianhong Zhou
Journal:  RSC Adv       Date:  2020-01-29       Impact factor: 4.036

7.  A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis.

Authors:  Yi Ma; Shaojun Zhao; Shutao Shen; Shixiong Fang; Zulu Ye; Zhi Shi; An Hong
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.